@article{TBCR116948,
author = {Xu Liang and Guohong Song},
title = {Progress of Trop-2-targeted antibody-drug conjugates in HER-2-negative breast cancer: a mini-review},
journal = {Translational Breast Cancer Research},
volume = {7},
number = {0},
year = {2026},
keywords = {},
abstract = {Breast cancer (BC) persists as a major cause of deaths associated with cancer among women globally, emphasizing the urgent need for innovative therapies. Trophoblast cell surface antigen 2 (Trop-2), a transmembrane glycoprotein involved in tumor growth, proliferation, and metastasis, has emerged as a promising therapeutic target. Trop-2-targeted antibody-drug conjugates (ADCs) improve the efficacy and reduce the safety concerns while compared to traditional chemotherapy by selectively delivering cytotoxic agents to tumor cells that express Trop-2. The expression of Trop-2 is higher in many solid tumors and is associated with poor prognosis. Various Trop-2-targeted ADCs, such as sacituzumab govitecan (SG), sacituzumab tirumotecan (SKB264), and datopotamab deruxtecan (Dato-DXd), are being actively investigated for advanced triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) BC. This review discusses the clinical progress and outcomes of these Trop-2 ADCs, their potential utility in combination with immunotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors and the ongoing clinical trials, and their efficacy in the treatment of patients with brain metastases, shaping the future of Trop-2-directed cancer treatment. Overall, Trop-2-targeted ADCs were promising in treating HER2− BC, with the potential to improve patient outcomes, enhance the quality of life, and pave the way for future Trop-2-focused research. Especially, SG has shown substantial efficacy in treating both TNBC and HR+/HER2− BC, with a tolerable safety profile, and an encouraging efficacy over standard chemotherapy. Trop-2 ADCs have made significant progress in BC therapy; however, many challenges remain, which require further investigation.},
issn = {2218-6778}, url = {https://tbcr.amegroups.org/article/view/116948}
}